Equillium (EQ) Non-Current Debt (2017 - 2023)
Equillium (EQ) reported Non-Current Debt of $1.8 million for Q1 2023, down 75.02% year-over-year from $7.4 million in Q1 2022, and down 43.16% quarter-over-quarter from $3.2 million in Q4 2022.
Equillium (EQ) Non-Current Debt (2017 - 2023) Analysis & Trends
Equillium (EQ) has 7 years of Non-Current Debt data on file, last reported at $1.8 million in Q1 2023.
- Non-Current Debt for Q1 2023 came in at $1.8 million, down 75.02% year-over-year; the trailing twelve-month figure through Mar 2023 was $1.8 million (down 75.02% YoY), and the FY2022 annual result was $3.2 million, down 62.98% from the prior year.
- Non-Current Debt declined to $1.8 million in Q1 2023 per EQ's latest filing, from $3.2 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $10.1 million in Q2 2021 and troughed at $1.8 million in Q1 2023.
- A 5-year average of $7.6 million and a median of $8.8 million in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2019 and 2023: Non-Current Debt soared 654.32% in 2019, then plunged 75.02% in 2023.
- A 5-year view of Non-Current Debt shows it stood at $9.7 million in 2019, then fell by 14.52% to $8.3 million in 2020, then grew by 5.74% to $8.8 million in 2021, then slumped by 62.98% to $3.2 million in 2022, then tumbled by 43.16% to $1.8 million in 2023.
- Business Quant data shows EQ's Non-Current Debt at $1.8 million in Q1 2023, $3.2 million in Q4 2022, and $4.6 million in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 1.84 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 3.24 Mn |
| Dec 31, 2022 | 3.24 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 5.99 Mn |
| Jun 30, 2022 | 5.99 Mn |
| Mar 31, 2022 | 7.37 Mn |
| Mar 31, 2022 | 7.37 Mn |
| Dec 31, 2021 | 8.75 Mn |
| Dec 31, 2021 | 8.75 Mn |
| Sep 30, 2021 | 8.87 Mn |
| Sep 30, 2021 | 8.87 Mn |
| Jun 30, 2021 | 10.07 Mn |
| Jun 30, 2021 | 10.07 Mn |
| Mar 31, 2021 | 7.51 Mn |
| Mar 31, 2021 | 7.51 Mn |
| Dec 31, 2020 | 8.28 Mn |
| Dec 31, 2020 | 8.28 Mn |